SCHEMBL3498795

SCHEMBL3498795

O=c1[nH]c2cccc(Br)c2c(=O)o1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.52
CFD P00746 1/20 0.52
FEN1 P39748 1/20 0.47
OGT O15294 1/20 0.46
CCNE2 O96020 2/20 0.41
CDK4 P11802 2/20 0.41
CCND1 P24385 2/20 0.41
CCNE1 P24864 2/20 0.41
CDK2 P24941 2/20 0.41
CAMK2B Q13554 2/20 0.41
CAMK2G Q13555 2/20 0.41
CAMK2D Q13557 2/20 0.41
CAMK2A Q9UQM7 2/20 0.41
CCNB2 O95067 1/20 0.41
CDK1 P06493 1/20 0.41
CCNB1 P14635 1/20 0.41
PRKACA P17612 1/20 0.41
PRKACG P22612 1/20 0.41
PRKACB P22694 1/20 0.41
CCNB3 Q8WWL7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL619937 0.81 F2 (0.52) F2CFDOGTPDGFRAMAPK8
SCHEMBL17203101 0.78 F2 (0.52) F2CFDOGTPDGFRAMAPK8
SCHEMBL1203402 0.78 F2 (0.52) F2CFDFEN1OGTPDGFRA
SCHEMBL147448 0.78 F2 (0.52) F2CFDFEN1OGTGPR17
SCHEMBL3987671 0.78 F2 (0.52) F2CFDOGTPDGFRAMAPK8
SCHEMBL5310423 0.78 F2 (0.52) F2CFDOGTCDK2CDK1
SCHEMBL1431472 0.77 OGT (0.48) F2CFDFEN1OGTMAOA
SCHEMBL10343102 0.76 F2 (0.50) F2CFDOGTPDGFRAMAPK8
SCHEMBL3981208 0.75 F2 (0.41) F2CFDFEN1OGTCDK5
SCHEMBL4509421 0.75 F2 (0.49) F2CFDOGTCDK2CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4695250-A1 TETRACYCLIC COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS Aurigene Oncology Limited (IN) 2026-02-18 EP disclosed
US-20250376457-A1 DICHLOROPHENOL HSD17B13 INHIBITORS AND USES THEREOF INIPHARM INC (US) 2025-12-11 US disclosed
US-20250171452-A1 TRYPTANTHRIN DERIVATIVES AND USES THEREOF VISCIENT BIO, INC. 2025-05-29 US disclosed
US-20250100993-A1 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2025-03-27 US disclosed
EP-4514804-A1 TRYPTANTHRIN DERIVATIVES AND USES THEREOF Viscient Bio, Inc. (US) 2025-03-05 EP disclosed
CN-119487031-A Tryptanthrin derivatives and uses thereof 威森特生物公司 2025-02-18 CN disclosed
US-20250049929-A1 NOVEL TETRAHYDROQUINOLINES AND PROTEOLYSIS TARGETING CHIMERA (PROTACS) COMPRISING THEM AS DEGRADERS OF SMARCA SCHOOL OF LIFE SCIENCES, UNIVERSITY OF DUNDEE (GB) 2025-02-13 US disclosed
CN-119032090-A 2-Substituted thiazole HSD17B13 inhibitors and uses thereof 伊尼制药公司 2024-11-26 CN disclosed
WO-2024214019-A1 TETRACYCLIC COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS AURIGENE ONCOLOGY LIMITED (IN) 2024-10-17 WO disclosed
EP-4408846-A1 NOVEL TETRAHYDROQUINOLINES AND PROTEOLYSIS TARGETING CHIMERA (PROTACS) COMPRISING THEM AS DEGRADERS OF SMARCA Boehringer Ingelheim International GmbH (DE) 2024-08-07 EP disclosed
EP-0226282-A2 Heterocyclic compounds and their preparation and use A/S FERROSAN (DK) 1987-06-24 EP disclosed
EP-0100906-B1 TRI- AND TETRACYCLIC IMIDAZO(1,5-A)(1,4)BENZODIAZEPIN-1-CARBOXYLIC-ACID DERIVATIVES F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1987-05-13 EP disclosed
US-4489003-A ANTICONVULSANTS, TRANQUILLIZERS HOFFMANN-LA ROCHE INC. (US) 1984-12-18 US disclosed
EP-0059389-B1 IMIDAZODIAZEPINES, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1984-12-12 EP disclosed
EP-0100906-A2 Tri- and tetracyclic imidazo(1,5-a)(1,4)benzodiazepin-1-carboxylic-acid derivatives F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1984-02-22 EP disclosed
US-4353827-A ANTICONVULSIVE, ANXIOLYTIC HOFFMANN-LA ROCHE INC. (US) 1982-10-12 US disclosed
US-4352817-A ANTIDOTE FOR TRANQUILLIZING EFFECTS OF 1,4-BENZODIAZEPINES HOFFMANN-LA ROCHE INC. (US) 1982-10-05 US disclosed
EP-0059391-A1 Imidazodiazepines, process for their preparation and pharmaceutical compositions containing them F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1982-09-08 EP disclosed
EP-0059389-A1 Imidazodiazepines, process for their preparation and medicines containing them F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1982-09-08 EP disclosed
US-4041025-A FOR HYDROPHOBIC FIBERS SUCH AS POLYESTERS, YELLOW TO BLUE-GREEN SHADES BASF AKTIENGESELLSCHAFT (DT) 1977-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250100993-A1 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF HSD17B1, HSD17B3, HSD17B13 F2 2976/4885CFD 4264/4885FEN1 1124/4885
US-20250376457-A1 DICHLOROPHENOL HSD17B13 INHIBITORS AND USES THEREOF HSD17B1, HSD17B3, HSD17B13 F2 2436/4885CFD 4276/4885FEN1 1367/4885
US-20250171452-A1 TRYPTANTHRIN DERIVATIVES AND USES THEREOF IDO2, IDO1, TPSB2 F2 1468/4885CFD 2381/4885FEN1 4740/4885
US-20250049929-A1 NOVEL TETRAHYDROQUINOLINES AND PROTEOLYSIS TARGETING CHIMERA (PROTACS) COMPRISING THEM AS DEGRADERS OF SMARCA SMARCC1, SMARCE1, SMARCA1 F2 3784/4885CFD 4763/4885FEN1 1399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.